Rongsong Ling

10PUBLICATIONS
25CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunologyInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Apr 28, 2025
Resistance to anti-LAG-3 plus anti-PD-1 therapy in head and neck cancer is mediated by Sox9+ tumor cells interaction with Fpr1+ neutrophils.

Xiaocheng Wang, Maosheng Cheng, Shuang Chen

|Feb 20, 2025
Neoadjuvant chemotherapy plus anlotinib in the treatment of resectable head and neck squamous cell carcinoma: A pilot phase II trial.

Qianting He, Shuojin Huang, Dongxiao Tang

|Aug 16, 2024
ITGB6 modulates resistance to anti-CD276 therapy in head and neck cancer by promoting PF4+ macrophage infiltration.

Caihua Zhang, Kang Li, Hongzhang Zhu

|Apr 15, 2024
Single cell analysis unveils B cell-dominated immune subtypes in HNSCC for enhanced prognostic and therapeutic stratification.

Kang Li, Caihua Zhang, Ruoxing Zhou

|Apr 01, 2024
CD276-dependent efferocytosis by tumor-associated macrophages promotes immune evasion in bladder cancer.

Maosheng Cheng, Shuang Chen, Kang Li

|Feb 29, 2024
Single-cell transcriptomics reveals cell atlas and identifies cycling tumor cells responsible for recurrence in ameloblastoma.

Gan Xiong, Nan Xie, Min Nie

Pageof 2

Frequent Collaborators

4 joint publications

Demeng Chen

3 joint publications

Shuibin Lin

3 joint publications

Cheng Wang

2 joint publications

Hui Han